| Bioactivity | Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM)[1]. |
| Invitro | Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性，在 H929 细胞中的 EC50 值为 0.15 nM，在MM.1R 细胞系中为 0.06 nM，在 RPMI 8226 细胞系中为 0.45 nM[1]。Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 +人 BM 单核细胞，并诱导人 BM 单核细胞的细胞毒性[1]。 |
| In Vivo | Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG（NOD/SCID/γc-/）小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性[1]。 Animal Model: |
| Name | Teclistamab |
| CAS | 2119595-80-9 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kodandaram Pillarisetti, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. |